Detalhe da pesquisa
1.
Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.
Cardiovasc Drugs Ther
; 2023 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37318685
2.
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Cardiovasc Drugs Ther
; 33(1): 87-95, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30675708
3.
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
JACC Heart Fail
; 9(8): 578-589, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34325888
4.
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
J Am Coll Cardiol
; 77(3): 243-255, 2021 01 26.
Artigo
Inglês
| MEDLINE | ID: mdl-33197559
5.
Intravascular ultrasound guided directional atherectomy versus directional atherectomy guided by angiography for the treatment of femoropopliteal in-stent restenosis.
Ther Adv Cardiovasc Dis
; 12(1): 17-22, 2018 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-29265002